Final Exam Study Guide NUR 2790: Professional Nursing III( Complete Solution Rated A}100%

Final Exam Study Guide NUR 2790: Professional Nursing III MODULE 1: CELLULAR REGULATION Cancer  Primary vs. Secondary prevention Primary CA prevention: removal of “at risk” tissue, chemopr even tion, vaccination (HPV) Secondary CA prevention: regular screening  Risk factors/warning signs (CAUTION mneumonic) C: change in bowel/bladder function A: a sore throat that does not heal U: unusual bleeding T: thickening lumps I: indigestion/difficulty swallowing O: obvious change in mole N: nagging cough/hoarseness  Treatment types, side effects/complications (& treatment/nursing care of side effects/complications) Surgery: can be prophylactic, diagnostic, curative, palliative SE/complications: removed organs and tissues lose function, removal of organs does not necessarily rid cancer Radiation: destroy cancer cells with minimal damaging effects of surrounding normal cells SE/complications: radiation dermatitis, altered taste/fatigue, atherosclerosis, coronary artery disease, fibrosis, scarring, bone marrow suppression Nursing care: provide accurate info, skin care (wash gently with soap and water, avoid scrubbing), do not remove temporary ink markings, provide nutritional support, care of xerostomia (administer saliva substitutes, lozenges, mouth rinses), reduce risk for bone fracture, encourage exercise and sleep interventions to treat fatigue Chemotherapy: treatment of cancer using antineoplastic drugs (cytotoxic systemic therapy) SE/complications: dosage and scheduling (dose-limiting side effects may impact), extravasation and vesicants, bone marrow suppression (neutropenia, anemia, thrombocytopenia), mucositis (inflammation of oral mucosa) alopecia (hair loss), chemo brain, chemo-induced peripheral neuropathy, fatigue Nursing care: epo-alfa/Epogen, blood products, no flossing, soft toothbrush, no razors, no NSAIDS, treat nausea (peppermint oil, Zofran, fluids, room temperature food, alcohol swabs) Immunotherapy: enhances and alters pt’s biological response to cancer cells via direct antitumor activity